Scarica l'app Stockscreener
0.3211
2.70%
-0.0089
Precedente Chiudi:
$0.33
Aprire:
$0.318
Volume 24 ore:
966.88K
Relative Volume:
0.05
Capitalizzazione di mercato:
$21.28M
Reddito:
$1.16M
Utile/perdita netta:
$-37.28M
Rapporto P/E:
-0.494
EPS:
-0.65
Flusso di cassa netto:
$-33.81M
1 W Prestazione:
-19.60%
1M Prestazione:
+100.69%
6M Prestazione:
+16.59%
1 anno Prestazione:
-78.59%
Intervallo 1D:
$0.3056
$0.3265
Intervallo di 1 settimana:
$0.3056
$0.4477
Portata 52W:
$0.1406
$3.5299
Glycomimetics Inc Stock (GLYC) Company Profile
Nome
Glycomimetics Inc
Settore
Industria
Telefono
240-243-1201
Indirizzo
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Confronta GLYC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| GLYC | 0.323 | 21.28M | 1.16M | -37.28M | -33.81M | -0.65 |
| VRTX | 449.87 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.58 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.99 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.18 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.15 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-26 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-22 | Iniziato | CapitalOne | Overweight |
| 2021-11-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-11-14 | Iniziato | ROTH Capital | Buy |
| 2019-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-05 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2018-12-18 | Iniziato | H.C. Wainwright | Buy |
| 2016-07-26 | Iniziato | SunTrust | Buy |
| 2015-03-17 | Reiterato | Stifel | Buy |
Mostra tutto
Glycomimetics Inc Borsa (GLYC) Ultime notizie
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics: Q3 Earnings Snapshot - Darien Times
Crescent Biopharma to Showcase Cancer Drug Pipeline at Jefferies Healthcare Conference | GLYC Stock News - StockTitan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, PFIE, GLYC on Behalf of Shareholders - The Malaysian Reserve
GlycoMimetics and Crescent Biopharma Update Investor Presentation in Connection with Proposed Merger - Defense World
Finansavisen - Finansavisen
RA Capital Management's Strategic Acquisition of GlycoMimetics I - GuruFocus.com
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - BioSpace
Top 3 Penny Stocks to Watch Today – October 31, 2024 - The Global Domains News
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
Shares of Biotech Company Up Over 100% Premarket Following Merger & Funding Announcement - MSN
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYC - WICZ
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYC - GlobeNewswire Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALTR, PFIE, GLYC on Behalf of Shareholders - Marketscreener.com
What Do Wall Street Analysts Think About GlycoMimetics Inc (NASDAQ: GLYC) Stock? - Stocks Register
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc.GLYC - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, ALTR, GLYC on Behalf of Shareholders - The Malaysian Reserve
GlycoMimetics’ Acquisition of Crescent Biopharma - Global Legal Chronicle
GlycoMimetics, Canaan, PayPal: 3 Stocks Retail Is Most Bullish On Today - MSN
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc.GLYC - Business Wire
3 Penny Stocks to Watch Now, 10/31/24 - TipRanks
GlycoMimetics Announces Merger Agreement with Crescent Biopharma: A Look at the Details - Defense World
GlycoMimetics To Acquire Crescent Biopharma - FinSMEs
Kuehn Law Encourages PFIE, GLYC, RVNC, and RCM Investors to Contact Law Firm - Morningstar
GlycoMimetics soars on news of M&A deal with Crescent Biopharma - The Pharma Letter
GlycoMimetics Announces Merger with Crescent Biopharma - Yahoo Finance
GlycoMimetics Insider Confidence Rewarded, Stock Hits US$11m Market Cap - Simply Wall St
Alphabet, Integrated Media, GlycoMimetic: 3 Stocks Making Retail Most Bullish Pre-Market Today - Barchart
Biotech Up Over +100% Premarket Following Merger And Funding Announcement - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Profire Energy, Inc. (Nasdaq – PFIE), Cepton, Inc. (Nasdaq – CPTN), GlycoMimetics, Inc. (Nasdaq – GLYC), ARC Document Solutions, Inc. (NYSE – ARC) - ForexTV.com
Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results - Benzinga
GlycoMimetics Stock Triples To Become Top Gainer On Crescent Biopharma Merger Deal: Retail Goes Wild - Barchart
GlycoMimetics Shares Are Soaring Tuesday: Here's Why - Benzinga
Crescent Inks Oncology Merger With $200M In Private Funding - Law360
S&P 500 Communication Services [Sector] (SRTS) QuotePress Release - The Globe and Mail
GlycoMimetics Agrees to Acquire Crescent Biopharma - MarketWatch
Crescent rolls up to Glycomimetics merger, $200M in new bread - BioWorld Online
Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders - Marketscreener.com
TSX 60 ESG Index (TSXE) QuotePress Release - The Globe and Mail
US Stocks Mixed; McDonald's Posts Upbeat Earnings - Benzinga
TSX Renewable and Clean Tech Index (TXCT) QuotePress Release - The Globe and Mail
Crescent inks GlycoMimetics merger, securing Nasdaq listing and $200M for hot cancer program - Fierce Biotech
GlycoMimetics skyrockets on buyout deal - MSN
Rockville biotech GlycoMimetics to be acquired - The Business Journals
GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders - Business Wire
GlycoMimetics enters acquisition agreement with Crescent Biopharma - TipRanks
GlycoMimetics Agrees to Be Taken Private by Crescent Biopharma - MarketWatch
Glycomimetics Shares Fall After Leukemia Treatment Trial Misses Key Goal - MarketWatch
Glycomimetics Inc Azioni (GLYC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Glycomimetics Inc Azioni (GLYC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10% Owner |
Aug 07 '24 |
Sale |
0.18 |
61,488 |
11,197 |
6,578,438 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 05 '24 |
Sale |
0.19 |
164,523 |
30,996 |
6,695,658 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 06 '24 |
Sale |
0.18 |
55,732 |
10,188 |
6,639,926 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 02 '24 |
Sale |
0.20 |
286,200 |
57,354 |
6,860,181 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 01 '24 |
Sale |
0.22 |
63,564 |
13,743 |
7,146,381 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 30 '24 |
Sale |
0.22 |
756,835 |
167,185 |
7,209,945 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 29 '24 |
Sale |
0.24 |
363,949 |
85,637 |
7,966,780 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 26 '24 |
Sale |
0.24 |
258,335 |
62,440 |
8,330,729 |
| Rock Edwin | Chief Medical Officer |
Jun 20 '24 |
Buy |
0.25 |
190,000 |
48,108 |
565,403 |
| Rock Edwin | Chief Medical Officer |
Jun 21 '24 |
Buy |
0.27 |
115,000 |
30,716 |
680,403 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):